News & Press Releases

Depression Disconnect: GeneSight^® Mental Health Monitor Shows Misunderstanding of Depression and Treatment

April 27, 2021

Depression Disconnect: GeneSight® Mental Health Monitor Shows Misunderstanding of Depression and Treatment New poll shows 83% of people with depression agree life would be easier if others could understand their depression…

GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels

February 8, 2021

SALT LAKE CITY, Feb. 08, 2021 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research has published…

Suffering in Silence: Two-Thirds of Older Adults Say They Won’t Treat Their Depression

November 17, 2020

New nationwide poll shows 1 in 3 respondents age 65+ think they can just “snap out of it” SALT LAKE CITY, Nov. 17, 2020 – A new nationwide poll, the…

Myriad Launches New GeneSight^® Psychotropic Patient Collection Kit

July 1, 2020

Clinicians Seeing Patients Remotely Can Now Offer Home DNA Sample Collection SALT LAKE CITY, July 1, 2020 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision…

New Study Demonstrates GeneSight Psychotropic Better Predicts Blood Drug Levels When Compared to Single-Gene Testing

June 8, 2020

Study Reviewed Citalopram and Escitalopram SALT LAKE CITY, June 08, 2020 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today a newly published…

Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight^® Psychotropic Test in People with Major Depressive Disorder

April 20, 2020

New Article Published Online in the Journal Pharmacogenomics SALT LAKE CITY, April 20, 2020 – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics…

GeneSight® Improved Clinical Outcomes. HAM-D6 Analysis Shows

January 6, 2020

SALT LAKE CITY, Jan. 06, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a…

GeneSight^® Psychotropic Test Improved Clinical Outcomes for People with Depression Who Were Taking Medications with Gene-Drug Interactions

November 6, 2019

New Analysis of GUIDED Trial Shows GeneSight Test Results Led to Statistically Significant Improvements in Remission, Response and Symptoms SALT LAKE CITY, Nov. 06, 2019 (GLOBE NEWSWIRE) — Myriad Genetics,…

Landmark Study Shows GeneSight^® Test Led to Significant Improvement in Mental Health Outcomes for Patients with Major Depressive Disorder

May 7, 2018

Data Presented at APA Show 50 Percent Improvement in Remission and 30 Percent Improvement in Response for GeneSight versus Treatment as Usual (TAU) SALT LAKE CITY, May 7, 2018 –…